Provided by Tiger Trade Technology Pte. Ltd.

Scholar Rock Holding Corp

49.37
-0.6300-1.26%
Pre-market: 49.790.4200+0.85%06:49 EDT
Volume:3.66M
Turnover:180.91M
Market Cap:6.01B
PE:-14.69
High:50.65
Open:50.01
Low:48.59
Close:50.00
52wk High:61.76
52wk Low:27.07
Shares:121.79M
Float Shares:107.73M
Volume Ratio:1.40
T/O Rate:3.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3601
EPS(LYR):-3.4845
ROE:-167.77%
ROA:-58.82%
PB:23.69
PE(LYR):-14.17

Loading ...

Analysts’ Top Healthcare Picks: Alnylam Pharma (ALNY), Scholar Rock Holding (SRRK)

TIPRANKS
·
Yesterday

Scholar Rock says FDA requested pregnancy safety study for Isembyld

TIPRANKS
·
Yesterday

Scholar Rock Shares Fall After Barclays Downgrade

MT Newswires Live
·
Yesterday

Scholar Rock Faces Early Isembyld Launch Friction From FDA Safety Requirements, Truist Says

MT Newswires Live
·
Yesterday

Scholar Rock Holding Price Target Raised to $70.00/Share from $64.00 by Wedbush

Dow Jones
·
Sep 15

Scholar Rock Holding Corporation : H.c. Wainwright Raises Target Price to $70 from $65

THOMSON REUTERS
·
Sep 15

U.S. Research Roundup-Eli Lilly, McDonald's, Welltower

Reuters
·
Sep 15

Scholar Rock downgraded to Equal Weight from Overweight at Barclays

TIPRANKS
·
Sep 15

Kestra Medical Technologies Q1 Revenue Beats Estimates, Raises FY Revenue Outlook

Reuters
·
Sep 15

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Amid AI Pullback

MT Newswires Live
·
Sep 14

Scholar Rock Says Its First Muscle-Targeted SMA Therapy Will Cost About $310,000 Annually

Reuters
·
Sep 14

Wedbush Sticks to Their Buy Rating for Scholar Rock Holding (SRRK)

TIPRANKS
·
Sep 14

Scholar Rock Holding Price Target Maintained with a $64.00/Share by Wedbush

Dow Jones
·
Sep 14

U.S. Stocks on the MOVE-US Energy Stocks, Baldwin, Johnson & Johnson

Reuters
·
Sep 14

Scholar Rock Exec Says Its First Drug to Target Muscle Loss in Spinal Mus­Cu­Lar at­Ro­Phy Has a Wholesale Acquisition Cost of $11,659 for a Single Use Vial - Conf.call

THOMSON REUTERS
·
Sep 14

Scholar Rock Exec Says Co Expects the Annual Net Cost in the U.S. for a Typical Patient to be Approximately $310,000

THOMSON REUTERS
·
Sep 14

Scholar Rock price target raised to $84 from $76 at BMO Capital

TIPRANKS
·
Sep 14

Top Premarket Gainers

MT Newswires Live
·
Sep 14

Truist Raises Price Target on Scholar Rock Holding to $76 From $55, Keeps Buy Rating

MT Newswires Live
·
Sep 14

Scholar Rock Shares up 11.6% Premarket After FDA Nod for First Muscle-Targeted Drug for Type of Genetic Disease

THOMSON REUTERS
·
Sep 14